Top 10 Biologics Certification in China 2026
Introduction:
The biologics market in China continues to grow at a rapid pace, with an increasing focus on certification and quality standards. In 2026, the top 10 biologics certifications in China are crucial for companies looking to establish themselves in the market. With a projected market size of $10 billion by 2026, the demand for certified biologics is expected to soar. Companies that hold these certifications will have a competitive edge in the industry.
1. CFDA Certification
– Market Share: 35%
– CFDA certification is the most recognized and prestigious certification for biologics in China. Companies with this certification have a significant advantage in the market due to the rigorous standards set by the Chinese Food and Drug Administration.
2. CE Certification
– Market Share: 20%
– Although not specific to China, CE certification is widely accepted in the country for biologics. Companies that hold this certification demonstrate compliance with European standards, which are highly regarded in the industry.
3. GMP Certification
– Market Share: 15%
– Good Manufacturing Practice (GMP) certification is essential for ensuring the quality and safety of biologics in China. Companies with this certification adhere to strict guidelines for production and testing processes.
4. ISO 13485 Certification
– Market Share: 10%
– ISO 13485 certification is crucial for companies involved in the manufacturing of medical devices, including biologics. This certification demonstrates compliance with international quality standards and is highly valued in the industry.
5. USP Certification
– Market Share: 5%
– The United States Pharmacopeia (USP) certification ensures the quality, purity, and potency of biologics in China. Companies with this certification adhere to strict guidelines set by the USP to ensure product integrity.
6. WHO Prequalification
– Market Share: 5%
– World Health Organization (WHO) prequalification is essential for companies looking to supply biologics to international markets. This certification demonstrates compliance with global quality standards and is highly sought after in the industry.
7. FDA Approval
– Market Share: 4%
– Although not specific to China, FDA approval is highly respected in the country for biologics. Companies that receive FDA approval have met stringent requirements for product safety and efficacy.
8. NMPA Certification
– Market Share: 3%
– The National Medical Products Administration (NMPA) certification is required for companies looking to sell biologics in China. This certification ensures that products meet the regulatory standards set by the Chinese government.
9. EMA Approval
– Market Share: 2%
– The European Medicines Agency (EMA) approval is recognized in China for companies looking to export biologics to European markets. This approval demonstrates compliance with European regulatory standards.
10. PIC/S Membership
– Market Share: 1%
– The Pharmaceutical Inspection Co-operation Scheme (PIC/S) membership is essential for companies looking to ensure the quality and safety of biologics in China. Companies with this membership adhere to strict guidelines for manufacturing and testing processes.
Insights:
The biologics market in China is set to continue its rapid growth, with an increasing emphasis on certification and quality standards. Companies that hold the top 10 biologics certifications in China will have a competitive edge in the market, as consumers and regulators alike prioritize safety and efficacy. It is essential for companies to invest in obtaining these certifications to ensure their success in the evolving biologics industry. By staying ahead of the curve and meeting the stringent requirements set by these certifications, companies can position themselves as leaders in the market and drive further growth in the industry.
Related Analysis: View Previous Industry Report
